Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)

被引：1
|
作者：
Mukohara, Toru
Ozaki, Yukinori
Kitano, Shigehisa
Yamashita, Makiko
Ikarashi, Daiki
Tsurutani, Junji
Iwasa, Tsutomu
Takahashi, Masato
Masuda, Norikazu
Futamura, Manabu
Minami, Hironobu
Matsumoto, Koji
Tanabe, Yuko
Kawabata, Hidetaka
Yoshimura, Kenichi
Takano, Toshimi
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P5-02-42
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-02-42
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Efficacy of taxane rechallenge in early metastatic relapse of HER2-negative breast cancer patients previously treated with taxane
    Vasseur, A.
    Carton, M.
    Guiu, S.
    Augereau, P.
    Uwer, L.
    Reynier, M. A. Mouret
    Levy, C.
    Eymard, J- C.
    Goncalves, A.
    Robert, M.
    Rouge, T. De La Motte
    Bachelot, T.
    Petit, T.
    Debled, M.
    Grinda, T.
    Desmoulins, I.
    Vanlemmens, L.
    Dalenc, F.
    Simon, G.
    Cabel, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S501 - S502
  • [32] Circulating tumor DNA as a predictive biomarker of response to palbociclib-fulvestrant in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer
    Darrigues, L.
    Pierga, J-Y
    Bernard, A.
    Bieche, I.
    Silveira, A.
    Michel, M.
    Sablin, M-P
    Cottu, P.
    Dubot, C.
    Geiss, R.
    Ricci, F.
    Proudhon, C.
    Bidard, F-C
    CANCER RESEARCH, 2019, 79 (04)
  • [33] Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
    Zielinski, Christoph
    Lang, Istvan
    Beslija, Semir
    Kahan, Zsuzsanna
    Inbar, Moshe J.
    Stemmer, Salomon M.
    Anghel, Rodica
    Vrbanec, Damir
    Messinger, Diethelm
    Brodowicz, Thomas
    BRITISH JOURNAL OF CANCER, 2016, 114 (02) : 163 - 170
  • [34] Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
    Domchek, Susan M.
    Robson, Mark
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Armstrong, Anne
    Conte, Pierfranco
    Bannister, Wendy
    Goessl, Carsten
    Runswick, Sarah
    Goel, Saurabh
    Tung, Nadine
    CANCER RESEARCH, 2018, 78 (04)
  • [35] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Yoshimoto, Masataka
    Takao, Shintaro
    Hirata, Masaru
    Okamoto, Yasushi
    Yamashita, Sumio
    Kawaguchi, Yoshihiro
    Takami, Makoto
    Furusawa, Hidemi
    Morita, Satoshi
    Abe, Chigusa
    Sakamoto, Junichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 331 - 338
  • [36] Trastuzumab improves the prognosis in HER2-positive when compared with HER2-negative patients. Trastuzumab plus vinorelbine in HER2-positive versus vinorelbine alone in HER2-negative metastatic breast cancer patients
    Papaldo, P
    Fabi, A
    Nardoni, C
    Pino, S
    Ferretti, G
    Carlini, P
    Mottolese, M
    Cianciulli, AM
    Alimonti, A
    Sperduti, I
    Di Cosimo, S
    Cognetti, F
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S72 - S72
  • [37] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Masataka Yoshimoto
    Shintaro Takao
    Masaru Hirata
    Yasushi Okamoto
    Sumio Yamashita
    Yoshihiro Kawaguchi
    Makoto Takami
    Hidemi Furusawa
    Satoshi Morita
    Chigusa Abe
    Junichi Sakamoto
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 331 - 338
  • [38] Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients
    Jacquet, E.
    Lardy-Cleaud, A.
    Pistilli, B.
    Franck, S.
    Cottu, P.
    Delaloge, S.
    Debled, M.
    Vanlemmens, L.
    Leheurteur, M.
    Guizard, A. V.
    Laborde, L.
    Uwer, L.
    Jacot, W.
    Berchery, D.
    Desmoulins, I.
    Ferrero, J. M.
    Perrocheau, G.
    Courtinard, C.
    Brain, E.
    Chabaud, S.
    Robain, M.
    Bachelot, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 95 : 93 - 101
  • [39] Neratinib plus fulvestrant plus trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
    Jhaveri, K.
    Eli, L. D.
    Wildiers, H.
    Hurvitz, S. A.
    Guerrero-Zotano, A.
    Unni, N.
    Brufsky, A.
    Park, H.
    Waisman, J.
    Yang, E. S.
    Spanggaard, I.
    Reid, S.
    Burkard, M. E.
    Vinayak, S.
    Prat, A.
    Arnedos, M.
    Bidard, F. -C.
    Loi, S.
    Crown, J.
    Bhave, M.
    Piha-Paul, S. A.
    Suga, J. M.
    Chia, S.
    Saura, C.
    Garcia-Saenz, J. a.
    Gambardella, V.
    de Miguel, M. J.
    Gal-Yam, E. N.
    Raphael, A.
    Stemmer, S. M.
    Ma, C.
    Hanker, A. B.
    Ye, D.
    Goldman, J. W.
    Bose, R.
    Peterson, L.
    Bell, J. S. K.
    Frazier, A.
    Diprimeo, D.
    Wong, A.
    Arteaga, C. L.
    Solit, D. B.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 885 - 898
  • [40] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
    Morimoto, Kosuke
    Moriwaki, Kensuke
    Shimozuma, Kojiro
    Nakayama, Takeo
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (12) : 1188 - 1197
12345